InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model

InMed Pharmaceuticals Inc.

Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.
Neurological assessments found no adverse effects on attitude, behavior, or motor function.
Company preparing for pre-IND meeting with FDA; advancing CMC scale-up and dose-ranging studies.
Data support design of first-in-human Phase 1 clinical trial for INM-901.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.